FDA Declares Eli Lilly's Weight Loss and Diabetes Drugs No Longer in Shortage

The FDA has announced that Eli Lilly's weight loss and diabetes medications, Jaro and Z bound, are no longer in shortage. These drugs, which help curb hunger by triggering the hormone GLP-1, have been in a designated shortage since 2022. Eli Lilly has expanded manufacturing efforts, making these medications commercially available. However, the FDA cautions that some patients and prescribers may still face occasional supply disruptions.